Kathryn Zoon Sells 17,202 Shares of Emergent Biosolutions (NYSE:EBS) Stock

Emergent Biosolutions Inc. (NYSE:EBS) Director Kathryn Zoon sold 17,202 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $8.40, for a total transaction of $144,496.80. Following the completion of the sale, the director directly owned 79,941 shares in the company, valued at $671,504.40. This represents a 17.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Emergent Biosolutions Trading Up 0.4%

EBS stock traded up $0.04 during midday trading on Monday, reaching $8.51. 839,196 shares of the company’s stock traded hands, compared to its average volume of 878,575. The company has a market capitalization of $439.23 million, a P/E ratio of -30.38 and a beta of 2.33. The company has a debt-to-equity ratio of 1.10, a current ratio of 4.29 and a quick ratio of 2.08. Emergent Biosolutions Inc. has a fifty-two week low of $4.71 and a fifty-two week high of $14.06. The business has a 50-day moving average price of $8.54 and a two-hundred day moving average price of $10.30.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.46. Emergent Biosolutions had a negative net margin of 1.27% and a positive return on equity of 10.76%. The company had revenue of $156.10 million for the quarter, compared to analyst estimates of $145.00 million.

Institutional Investors Weigh In On Emergent Biosolutions

Several institutional investors have recently bought and sold shares of EBS. Legal & General Group Plc acquired a new stake in Emergent Biosolutions in the second quarter worth about $31,000. Torren Management LLC acquired a new stake in Emergent Biosolutions in the fourth quarter worth about $37,000. CANADA LIFE ASSURANCE Co acquired a new stake in Emergent Biosolutions in the fourth quarter worth about $45,000. Raymond James Financial Inc. acquired a new stake in Emergent Biosolutions in the second quarter worth about $53,000. Finally, Farther Finance Advisors LLC lifted its holdings in Emergent Biosolutions by 361.3% in the fourth quarter. Farther Finance Advisors LLC now owns 6,163 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 4,827 shares during the period. Institutional investors and hedge funds own 78.40% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on EBS shares. Weiss Ratings lowered shares of Emergent Biosolutions from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, April 27th. HC Wainwright reduced their price target on shares of Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating for the company in a report on Monday, March 9th. Finally, Wall Street Zen downgraded shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Emergent Biosolutions has a consensus rating of “Hold” and a consensus price target of $12.00.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.